CatalYm

Germany
Bayern, Germany, Planegg
+49 89 200066440 ★

Company profile

CatalYm company profile

CatalYm is a biotechnology company committed to developing innovative immunotherapies for cancer patients. CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment and translates the therapeutic potential of neutralizing GDF-15 into meaningful clinical responses for patients with solid tumors. CatalYm’s CTL-002 program is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications and has the potential to expand the treatment horizon for current and future immunotherapies.

Business identity

Contact email
[email protected]
Phone number
+49 89 200066440
Operating status
Active
Company type
For Profit
Employee range
00011-00050 employees
Revenue range
$1K+
Founded
2016-01-01

Headquarters

Headquarters
Bayern, Germany, Planegg
Postal code
82152
Country code
DE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
4
Total equity funding
$260.9M
Last funding
Series D / $150M / 2024-07-16
Last equity funding
Series D / $150M
Investors
13
Lead investors
5
Founders
1
Articles
55

Founders and investors

Founders

Jörg Wischhusen

Lead investors

Bioqube VenturesBrandon CapitalCanaan PartnersJeito CapitalVesalius Biocapital Partners

Investors

BioGeneration VenturesBrandon CapitalCanaan PartnersForbion Capital PartnersOmega Funds

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.